SLS
SELLAS Life Sciences Group, Inc. Common Stock
Nasdaq · usd
SELLAS Life Sciences Group, Inc. Common Stock (SLS) trades at $13.66 (-8.08%) as of 7:59:30 PM EST on Nov 20, 2026, +20.35% over the past month. Market cap is $2.78B, with 6.7 days to cover in short interest.
Stock performance
How SELLAS Life Sciences Group, Inc. Common Stock (SLS) stock has performed from one day to one year, with its 52-week range.
- 1D
- -8.08%
- 1W
- +73.79%
- 1M
- +20.35%
- YTD
- +262.33%
- 1Y
- +781.29%
- 52-wk range
- $1.39 – $24.89
Key statistics
Today's trading snapshot for SLS: day range, open, previous close, volume and market cap.
- Day range
- $13.39 – $15.19
- Open
- $14.98
- Prev close
- $14.86
- Volume
- 15.48M
- Market cap
- $2.78B
- Shares out
- 201.95M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for SELLAS Life Sciences Group, Inc. Common Stock: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 21.13
- P/FCF
- —
- ROE
- -27.1%
- ROA
- -25.4%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 20, 2026
8-K filings
Material corporate events SELLAS Life Sciences Group, Inc. Common Stock has disclosed to the SEC on Form 8-K.
- Underwriting agreementNov 20, 2026
On November 18, 2026, SELLAS Life Sciences Group, Inc. ... entered into an underwriting agreement ... with J.P. Morgan Securities LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein.
- Clinical trial resultsNov 17, 2026
In the trial, GPS showed a 41% reduction in the risk of death (hazard ratio of 0.59) and a two-sided p=0.035 with a median OS of 24.0 months among GPS-treated patients versus 14.7 months with BAT.
- Quarterly earningsNov 12, 2026
On November 12, 2026, SELLAS Life Sciences Group, Inc. ("SELLAS") issued a press release (the "Press Release") announcing its financial results for the quarter ended September 30, 2026 and providing a corporate update.
- Material litigationJul 27, 2026
On July 24, 2026, the sole arbitrator in the arbitration proceeding rendered a decision dismissing the Company's claims. As permitted by HKIAC rules, the arbitrator administratively allocated a portion of 3D Medicines' legal fees and costs in the amount of approximately $1.0 million to be paid by the Company.
- Executive compensation changeJun 25, 2026
The Stergiou Amendment amends the Stergiou Employment Agreement to provide that certain payments made to Dr. Stergiou as part of his change in control severance benefits will be paid in a lump sum payment.
Dividend history and stock splits
SELLAS Life Sciences Group, Inc. Common Stock's recent dividend payments and stock splits.
Dividends
- $0.24ex-div Mar 24, 2011
- $0.42ex-div Dec 9, 2010
- $0.15ex-div Sep 9, 2010
- $0.09ex-div Jun 10, 2010
Splits
- 1-for-50Nov 8, 2019
- 1-for-20Nov 14, 2016
SLS short interest
How heavily SLS is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 6.7
- Short interest
- 57.13M
- Avg volume
- 8.53M
As of · reported to FINRA twice monthly.
SLS news
The latest news and headlines about SELLAS Life Sciences Group, Inc. Common Stock (SLS).
- SELLAS Life Sciences Announces Pricing of $150.0 Million Underwritten Public OfferingpositiveGlobeNewswire Inc.· Nov 18, 2026
- SELLAS anuncia resultados positivos del ensayo pivotal de fase 3 REGAL, que demuestran que la vacuna inmunoterapéutica contra el cáncer galinpepimut-S (GPS) produjo una mejora estadísticamente significativa y clínicamente relevante de la supervivencia global en pacientes con leucemia mieloide agudapositiveGlobeNewswire Inc.· Nov 17, 2026
- SELLAS Life Sciences Divulga Dados Positivos do Estudo REGAL Pivotal de Fase 3, Indicando que Galinpepimut-S (GPS), a Vacina Imunoterapêutica Contra o Câncer, Demonstrou uma Melhora Estatisticamente Significativa e Clinicamente Relevante na Sobrevida Global de Pacientes com Leucemia Mieloide AgudapositiveGlobeNewswire Inc.· Nov 17, 2026
- SELLAS Life Sciences Announces Positive Pivotal Phase 3 REGAL Trial Data Showing Immunotherapeutic Cancer Vaccine, Galinpepimut-S (GPS), Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with Acute Myeloid LeukemiapositiveGlobeNewswire Inc.· Nov 17, 2026
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc. - SLSnegativeGlobeNewswire Inc.· Sep 29, 2026
Frequently asked questions
What is the SELLAS Life Sciences Group, Inc. Common Stock (SLS) stock price today?
SELLAS Life Sciences Group, Inc. Common Stock (SLS) is trading at $13.66 (-8.08% on the day) as of 7:59:30 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.
What is SELLAS Life Sciences Group, Inc. Common Stock?
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications.
What is the short interest in SLS?
As of Oct 30, 2026, SLS has 57.13M shares short and 6.7 days to cover.
Does SELLAS Life Sciences Group, Inc. Common Stock (SLS) pay a dividend?
Yes. SELLAS Life Sciences Group, Inc. Common Stock (SLS)'s most recent dividend was $0.24 per share, with an ex-dividend date of Mar 24, 2011. Full SLS dividend history is available from the Massive API.
What exchange is SLS listed on?
SELLAS Life Sciences Group, Inc. Common Stock (SLS) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of SLS with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a SLS analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.